# A Study to Evaluate Immunotherapy Combinations in Participants With Gastrointestinal Malignancies

> **NCT03720678** · PHASE1 · COMPLETED · sponsor: **Arcus Biosciences, Inc.** · enrollment: 44 (actual)

## Conditions studied

- GastroEsophageal Cancer
- Colorectal Cancer

## Interventions

- **DRUG:** etrumadenant
- **DRUG:** mFOLFOX

## Key facts

- **NCT ID:** NCT03720678
- **Lead sponsor:** Arcus Biosciences, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-11-18
- **Primary completion:** 2021-01-27
- **Final completion:** 2021-06-25
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2024-05-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03720678

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03720678, "A Study to Evaluate Immunotherapy Combinations in Participants With Gastrointestinal Malignancies". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03720678. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*